

Washington University School of Medicine

Digital Commons@Becker

Open Access Publications

2018

Outpatient antibiotic prescription trends in the United States: A national cohort study

Michael J. Durkin

Washington University School of Medicine in St. Louis

S. Reza Jafarzadeh

Boston University

Kevin Hsueh

Washington University School of Medicine in St. Louis

Ya Haddy Sallah

Washington University School of Medicine in St. Louis

Kiraat D. Munshi

Express Scripts Holding Company

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Durkin, Michael J.; Jafarzadeh, S. Reza; Hsueh, Kevin; Sallah, Ya Haddy; Munshi, Kiraat D.; Henderson, Rochelle R.; and Fraser, Victoria J., "Outpatient antibiotic prescription trends in the United States: A national cohort study." *Infection Control & Hospital Epidemiology*. 39, 5. 584-586. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/6786

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors

Michael J. Durkin, S. Reza Jafarzadeh, Kevin Hsueh, Ya Haddy Sallah, Kiraat D. Munshi, Rochelle R. Henderson, and Victoria J. Fraser

ORIGINAL ARTICLE

Outpatient Antibiotic Prescription Trends in the United States: A National Cohort Study

Michael J. Durkin, MD, MPH;¹ S. Reza Jafarzadeh, DVM, MPVM, PhD;² Kevin Hsueh, MD;¹ Ya Haddy Sallah, MPH;¹ Kiraat D. Munshi, PhD;³ Rochelle R. Henderson, PhD;³ Victoria J. Fraser, MD¹ for the CDC Prevention Epicenters

OBJECTIVE. To characterize trends in outpatient antibiotic prescriptions in the United States.

DESIGN. Retrospective ecological and temporal trend study evaluating outpatient antibiotic prescriptions from 2013 to 2015.

SETTING. National administrative claims data from a pharmacy benefits manager PARTICIPANTS. Prescription pharmacy beneficiaries from Express Scripts Holding Company.

MEASUREMENTS. Annual and seasonal percent change in antibiotic prescriptions.

RESULTS. Approximately 98 million outpatient antibiotic prescriptions were filled by 39 million insurance beneficiaries during the 3-year study period. The most commonly prescribed antibiotics were azithromycin, amoxicillin, amoxicillin/clavulanate, ciprofloxacin, and cephalexin. No significant changes in individual or overall annual antibiotic prescribing rates were found during the study period. Significant seasonal variation was observed, with antibiotics being 42% more likely to be prescribed during February than September (peak-to-trough ratio [PTTR], 1.42; 95% confidence interval [CI], 1.39–1.61). Similar seasonal trends were found for azithromycin (PTTR, 2.46; 95% CI, 2.44–3.47), amoxicillin (PTTR, 1.52; 95% CI, 1.42–1.89), and amoxicillin/clavulanate (PTTR, 1.78; 95% CI, 1.68–2.29).

CONCLUSIONS. This study demonstrates that annual national outpatient antibiotic prescribing practices remained unchanged during our study period. Furthermore, seasonal peaks in antibiotics generally used to treat viral upper respiratory tract infections remained unchanged during cold and influenza season. These results suggest that inappropriate prescribing of antibiotics remains widespread, despite the concurrent release of several guideline-based best practices intended to reduce inappropriate antibiotic consumption; however, further research linking national outpatient antibiotic prescriptions to associated medical conditions is needed to confirm these findings.

Infect Control Hosp Epidemiol 2018;39:584–589

The selective pressures of both inpatient and outpatient antibiotic use have contributed to the evolution of increasingly drug-resistant bacteria. The Centers for Disease Control and Prevention (CDC) recognizes multidrug-resistant organisms and infections, such as *Clostridium difficile* infection (CDI) and carbapenem-resistant Enterobacteriaceae (CRE), as urgent threats to the US healthcare system.¹ It is estimated that the CDI alone causes 2,500,000 infections, 14,000 deaths, and \$1 billion in excess medical costs per year. Furthermore, the first pan-resistant CRE isolate in the United States, *mcr-1*, was recently identified, ushering us into the “post-antibiotic era.”² Truly, more responsible management of antibiotic utilization is urgently needed to limit the development of antibiotic resistance.

Significant scrutiny has been placed on antibiotic utilization in hospitals. The CDC has proposed comparing and monitoring antibiotic utilization among hospitals using the

standardized antimicrobial administration ratio.³ Furthermore, the Centers for Medicare and Medicaid Services has proposed a rule requiring all acute-care hospitals to have formal antibiotic stewardship programs to reduce inappropriate antibiotic use.⁴

Despite aggressive national action on inpatient antibiotic use, outpatient antibiotic utilization rates and appropriateness remains poorly studied. Conservative estimates suggest that up to 30% of outpatient antibiotic use among medical providers may be inappropriate.⁵ Mistreatment of viral respiratory tract conditions with antibiotics is particular concerning. For example, in one study, >70% of adult patients with pharyngitis were given an antibiotic prescription, while only 18% met treatment criteria for streptococcal pharyngitis.⁵ Sinusitis, also often a viral condition, was the number 1 medical condition associated with antibiotic prescriptions in a large national

Affiliations: 1. Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri; 2. Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, Massachusetts; 3. Express Scripts Holding Company, St Louis, Missouri.

PREVIOUS PRESENTATION. A poster presentation of this data was presented at SHEA 2017 on March 31, 2017, in St Louis, Missouri.

Received October 23, 2017; accepted January 23, 2018; electronically published March 8, 2018

© 2018 by The Society for Healthcare Epidemiology of America. All rights reserved. 0899-823X/2018/3905-0011. DOI: 10.1017/ice.2018.26

data set.⁵ Furthermore, children receive excessive antibiotics when influenza is circulating in the community.⁶ The objective of our study was to evaluate outpatient antibiotic prescription patterns over time, and in particular, to assess the presence of seasonal variation in use of common antibiotics. We hypothesize that the annual antibiotic prescription rate has declined annually and that the most common antibiotics will exhibit seasonal variation, with higher antibiotic prescription rates during the winter months corresponding to the distribution of upper respiratory viral illnesses, particularly influenza.

METHODS

Study Design and Data Source

This study is an ecological and temporal trend study involving retrospective analysis of outpatient antibiotic prescriptions from deidentified administrative claims data for the period between January 1, 2013, and December 31, 2015. Outpatient antibiotic prescription data were obtained for a sample of insured members whose pharmacy benefits were managed by a large pharmacy benefit management company, Express Scripts Holding Company.

Study Variables

Antibiotic utilization was initially evaluated on an annual basis for the 3-year period from 2013 to 2015. All systemic outpatient antibiotics were summed per calendar year. Eligibility was not controlled for during the study period. Hence, prescription rates per 1,000 beneficiaries were calculated using midpoint values of beneficiaries for each calendar year. Antibiotic costs were calculated by summing individual members' health insurance plan costs and out-of-pocket expenses. Costs per prescription were extracted and summed per calendar year and calculated as costs per 1,000 beneficiaries.

Data included total number of prescriptions, total number of prescribers, antibiotic name, number of antibiotic pills prescribed, date of prescription, cost of antibiotic prescription, and geographic location of prescriber by state. Prescription claims for members with missing or duplicate information were removed. In addition, reversed (unfilled) prescription claims were excluded from the analysis.

Analysis

Monthly prescription rates for all antibiotics were plotted for each of the 3 years examined in this study to visualize the seasonal variation. The 5 most commonly prescribed antibiotics in the database were plotted and assessed in a similar fashion. A seasonal pattern in health outcomes is often referred to events that happen with some regularity at fixed times or dates, or in distinct climatic periods; however, seasonality may not be specifically regular in its amplitude, timing, or shape.⁷

Seasonal variations in prescription counts were assessed by fitting log-linear Poisson regression models to monthly data. The magnitude of seasonal variations was quantified by

peak-to-trough ratio (PTTR), which is interpreted as a relative risk with the trough month as the reference level.⁸ Unlike the estimators based on geometrical models that assume a single peak 6 months subsequent to a trough, the estimator based on unadjusted Poisson regression provides flexibility in the pattern of seasonal variation and can adjust for the secular trend bias.

Overall temporal trends in antibiotics prescriptions were quantified and expressed as annual percent change through fitting linear regression models with autoregressive integrated moving average (ARIMA) errors to the natural logarithm of monthly rates.⁹ This allows accounting for the correlation of model errors over time (ie, autocorrelation) during the study period.¹⁰ Analyses for seasonality and trends were performed in R version 3.2.4 (R Foundation for Statistical Computing, Vienna, Austria). All other statistics including descriptive analyses were computed using SAS version 9.4 (SAS Institute, Cary, NC). The Washington University Office of Human Research Protection approved this study.

RESULTS

Annual Antibiotic Prescription Trend

Approximately 98 million antibiotic prescriptions were filled during the 3-year study period from a sample of nearly 39 million insured members (Table 1). The mean number of prescriptions per 1,000 beneficiaries was 826 between 2013 and 2015, and this number ranged from 830 to 849 annually. There was a decrease in the antibiotic prescription rate between 2013 and 2014, followed by an increase in 2015. Although the average individual antibiotic costs per beneficiary were modest (\$23 dollars per year), the overall costs in the cohort were enormous in our cohort, representing 840 million to nearly \$1 billion annually.

The 5 most commonly prescribed antibiotics were azithromycin, amoxicillin, amoxicillin/clavulanate, ciprofloxacin, and cephalexin (Table 2). Linear regression estimates of temporal trends expressed as annual percent change in prescriptions demonstrated no statistically significant changes in prescribing rates during the 36-month study period for all antibiotics as well as the top 5 most commonly prescribed antibiotics (Table 2).

TABLE 1. Numbers and Rates of Outpatient Antibiotic Prescriptions Within the Express Scripts Database, 2013 to 2015.

Year	No. of Prescriptions, Millions	No. of Prescriptions per 1,000 Beneficiaries	Total Drug Costs, \$	Cost per 1,000 Beneficiaries, \$
2013	29.95	829	902,658,788	24,994
2014	28.75	799	804,029,460	22,331
2015	28.98	851	764,731,899	22,460
Total	87.68	826	2,471,420,147	23,278

TABLE 2. Estimates of Average Antibiotic Use Annual Percent Change for Common Antibiotic Prescriptions Within the Express Scripts Database, 2013 to 2015.

Antibiotics	Average No. of Antibiotic Prescriptions per 1,000 Beneficiaries	Annual Change, % (95% CI)
All antibiotics	826	-1.18 (-8.07 to 6.21)
Azithromycin	443	-4.19 (-15.31 to 8.39)
Amoxicillin	433	1.87 (-5.27 to 9.56)
Amoxicillin/Clavulanate	242	4.05 (-1.61 to 10.04)
Ciprofloxacin	173	-2.26 (-4.73 to 0.27)
Cephalexin	186	1.07 (-1.94 to 4.18)

TABLE 3. Estimates of Seasonal Variation in Antibiotic Prescriptions Within the Express Scripts Database Expressed as Peak-to-Trough Ratios, 2013 to 2015.

Antibiotic	Peak-to-Trough Ratio (95% CI) ^a	Peak Month	Trough/Reference Month
All antibiotics	1.42 (1.39–1.61)	February	September
Azithromycin	2.46 (2.44–3.47)	February	August
Amoxicillin	1.52 (1.42–1.89)	February	August
Amoxicillin/Clavulanate	1.78 (1.68–2.29)	February	August
Ciprofloxacin	1.15 (1.15–1.22)	August	January
Cephalexin	1.22 (1.20–1.24)	August	January

^aConfidence interval does not include 1. Estimated peak and trough months were calculated via regression models and slightly vary from actual antibiotic prescription count data.

Seasonal Variation in Antibiotic Prescriptions

The overall antibiotic prescription rate varied significantly by month (Figure 1) with a seasonal peak observed in February that was 42% higher than the trough in September (PTTR, 1.42; 95% confidence interval [CI], 1.39–1.61). The top 3 antibiotics prescribed (azithromycin, amoxicillin, and amoxicillin/clavulanate) had similar winter-peaking trends (Table 3 and Figure 1). For example, usage of azithromycin, the most commonly prescribed medication in this study, increased by 146% in February compared to August (Table 3). Seasonal trends for the less commonly prescribed antibiotic medications, ciprofloxacin, and cephalexin, however, were reversed, with the highest prescribing month in the summer and the lowest prescribing month in the winter (Table 3 and Figure 1). Furthermore, the seasonal variation in the usage of ciprofloxacin and cephalexin was less pronounced; these medications had 15% and 22% increases in the peak month of August compared to the trough month of January, respectively (Table 3 and Figure 1).

DISCUSSION

Annual antibiotic prescribing rates remained unchanged over the course of our 3-year cohort study of more than 30 million

insured members. These findings are surprising given the increasing pressure from multiple professional societies to reduce inappropriate prescribing practices. Since the beginning of our study in 2013, the American Board of Internal Medicine (ABIM) Foundation, in conjunction with a number of medical professional societies, has released practical recommendations in their “Choosing Wisely” campaign to reduce inappropriate antibiotic prescribing practices for the following conditions: asymptomatic bacteriuria, suspected viral upper respiratory tract infections, stasis dermatitis for lower extremities, antibiotic prophylaxis for mitral valve prolapse, antibiotics for uncomplicated skin and soft-tissue infections after successful incision and drainage, inflamed epidermal cysts, uncomplicated acute tympanostomy tube otorrhea, and uncomplicated acute external otitis.¹¹ The Center for Disease Control and Prevention (CDC) also provides educational resources for healthcare professionals, policy makers, and the public to reduce inappropriate antibiotic use through the longstanding “Get Smart: Know When Antibiotics Work” program.¹²

The lack of any apparent change in utilization over the course of this study may support the findings of other studies suggesting that professional guidelines may not be the most effective form of influencing provider actions. Suda et al demonstrated a modest 2.6% decline in antibiotic prescriptions nationally in the United States between 2006 and 2010; however, only stratified statistical analyses were performed to evaluate this trend.¹³ Longer longitudinal data of primary care providers from the United Kingdom between 1995 and 2011 have shown mixed results from best practice guidelines alone. During this period, prescriptions for sore throats declined from 77% to 62% and prescriptions for otitis media increasing from 77% in to 85%.¹⁴ Similar findings have been observed for cesarean sections,¹⁵ management of pediatric femoral fractures,¹⁶ and thrombophilia screening.¹⁷ Clearly, we need more effective methods to disseminate and implement evidence-based guidelines for healthcare providers.

Several outpatient antimicrobial stewardship interventions have led to improved antibiotic utilization. Interventions as simple as posters placed in a patient waiting rooms can reduce antibiotic prescribing for acute respiratory tract infections.¹⁸ Some examples of more detailed interventions include antibiotic prescription benchmarking, audit and feedback, and education sessions.^{19,20}

Seasonal variation in antibiotic prescribing has been previously reported in the United States,^{13,21} Europe,^{22,23} Canada,²⁴ and Israel.²⁵ In each of these studies, overall antibiotic use was higher during the winter months. The rate of increase ranged between 21% and 42%, with our study at the top of the range. The higher rate of macrolide antibiotic prescribing during the winter months has been linked to inappropriate antibiotic prescribing for viral infections.^{23–25} Previous investigators have suggested that spikes in antibiotic prescriptions during winter months may represent inappropriate treatment for viral conditions, which tend to occur more frequently during winter months.^{13,21,26–28}




FIGURE 1. Monthly variation of rate of outpatient antibiotic use overall and stratified by the top 5 antibiotics. NOTE. Rx, prescription.

Many common bacterial infections also exhibit seasonal variation. For example, bloodstream infections,^{29,30} urinary tract infections,³¹ peritoneal dialysis infections,³² skin and soft-tissue infections,³³ and surgical site infections^{34–36} are all more common during the summer months. However, *Streptococcus pneumoniae*, community-acquired pneumonia, and methicillin-resistant *Staphylococcus aureus* pneumonia tend to be more common during the winter months.^{37–40} Therefore, at least some of the peak in antibiotic prescribing is likely related to appropriate treatment of bacterial conditions. Not surprisingly, ciprofloxacin and cephalexin, common antibiotics used for urinary tract infections and skin and soft-tissue infections, were associated with higher antibiotic use during the summer months in our study. These findings are novel and have not been described previously in the literature. Furthermore, these findings also highlight that precautions must be taken not to overgeneralize when analyzing antibiotic use. For example, moxifloxacin and ciprofloxacin are both fluoroquinolone antibiotics; however, moxifloxacin is more frequently used for respiratory tract infections, while ciprofloxacin is used primarily for urinary tract infections. Classifying these 2 agents together could misrepresent the different seasonal patterns in the prescriptions of these medications and the infections they are used to treat.

This study has several limitations. First, this cohort represents only insured patients, so the results may not be generalizable to the entire US population, including uninsured individuals. However, our results were similar to those of larger studies estimating antibiotic prescribing for the entire United States.¹³ Second, medications are captured only when the claims are processed, so prescription claims that are not processed (eg, during instances when individuals chose to pay for inexpensive antibiotics out-of-pocket without using their insurance) were not captured. Therefore, our data likely underestimates overall antibiotic utilization in our cohort. Third, our analysis does not include any microbiology or medical claims data; thus, we were unable to adequately assess the appropriateness of each antibiotic prescribed or the comorbidities of patients who received antibiotics. For example, some antibiotic prescriptions written during the winter months were likely appropriate for conditions like Streptococcal and Staphylococcal pneumonia, which are more common during winter months as well. Fourth, the data set that we used did not contain information at an individual patient level, so we were unable to determine whether our data contained a large number of antibiotic prescriptions for a few patients or a few antibiotics for a large number of patients. Similarly, because our analysis was limited to prescription counts, we did not evaluate differences in antibiotic prescription dose or duration of therapy in this analysis. Sixth, we did not compare influenza-like illness and antiviral prescription rates in our study. Although this would have been a nice additional evaluation, these are typically evaluated weekly (rather than monthly) and span calendar years, making comparisons using our data challenging. Additional analyses should be performed to more rigorously evaluate the

relationships among antiviral prescriptions, influenza-like illnesses, and antibiotic prescriptions.

In conclusion, there were no appreciable changes in overall antibiotic use over the 3-year study period in our cohort of more than 30 million privately insured individuals in the United States, despite the concurrent release of a number of guideline-based best practices designed to reduce inappropriate antibiotic consumption. Furthermore, we identified significant seasonal variation in antibiotic prescribing. Certain agents frequently associated with inappropriate management of upper respiratory tract infections, such as azithromycin, were prescribed at a higher rate during the winter months. Additional work is needed to better link antibiotic prescriptions to indications to better quantify and trend inappropriate antibiotic prescribing practices. However, in our opinion, additional interventions, beyond guidelines and educational materials, will be required to substantially improve antibiotic prescribing at a national level.

ACKNOWLEDGMENTS

The content is solely the responsibility of the authors and does not necessarily represent the official views of the Centers for Disease Control and Prevention or the National Institutes of Health.

Financial support: Research reported in this publication was supported by the Centers for Disease Control and Prevention epicenters program (grant no. U54CK000482) and the National Center for Advancing Translational Sciences of the National Institutes of Health (grant no. KL2TR00236).

Potential conflicts of interest: M.J.D. has created continuing educational materials for Medscape. Funding for those materials was provided to Medscape through an unrestricted educational grant from Merck. V.J.F. owns stock in Express Scripts Holding Company. K.D.M. and R.R.H. are employed by Express Scripts Holding Company and hold stocks in the company. All other authors report no conflicts of interest.

Address correspondence to Michael J. Durkin MD, MPH, Washington University School of Medicine, Campus Box 8051, 4523 Clayton Ave, St. Louis, MO, 63110 (mdurkin@wustl.edu).

REFERENCES

1. Antibiotic resistance threats in the United States. 2013. Centers for Disease Control and Prevention website. <https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf>. Published 2013. Accessed August 2, 2017.
2. McGann P, Snedrud E, Maybank R, et al. *Escherichia coli* harboring *mcr-1* and *blaCTX-M* on a novel IncF plasmid: first report of *mcr-1* in the USA. *Antimicrob Agents Chemother* 2016;60:4420–4421.
3. Standardized antimicrobial administration ratio table. Centers for Disease Control and Prevention website. <https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/aur/au-qrg-saartables.pdf>. Accessed on August 2, 2017.
4. CMS issues proposed rule that prohibits discrimination RH-AC, and promotes antibiotic stewardship in hospitals. Centers for Medicare and Medicaid website. <https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2016-Fact-sheets-items/2016-06-13.html>. Published 2016. Accessed August 2, 2017.
5. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010–2011. *JAMA* 2016;315:1864–1873.

6. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. *N Engl J Med* 2000;342:225–231.
7. Barnett AG, Dobson AJ. *Analysing Seasonal Health Data*. 1st ed. New York: Springer; 2010.
8. Christensen AL, Lundbye-Christensen S, Dethlefsen C. Poisson regression models outperform the geometrical model in estimating the peak-to-trough ratio of seasonal variation: a simulation study. *Comput Methods Programs Biomed* 2011;104:333–340.
9. Hankey BF, Ries LA, Kosary CL, et al. Partitioning linear trends in age-adjusted rates. *Cancer Cause Control* 2000;11:31–35.
10. Hyndman R, Athanasopoulos G. Forecasting: principles and practice. OTexts website. <https://www.otexts.org/fpp>. Published 2013. Accessed on August 2, 2017.
11. Choosing Wisely, an initiative of the American Board of Internal Medicine Foundation. Choosing Wisely website. <http://www.choosingwisely.org/>. Accessed August 2, 2017.
12. Get Smart programs and observances. Centers for Disease Control and Prevention website. <https://www.cdc.gov/getsmart/index.html>. Accessed August 2, 2017.
13. Suda KJ, Hicks LA, Roberts RM, Hunkler RJ, Taylor TH. Trends and seasonal variation in outpatient antibiotic prescription rates in the United States, 2006 to 2010. *Antimicrob Agents Chemother* 2014;58:2763–2766.
14. Hawker JJ, Smith S, Smith GE, et al. Trends in antibiotic prescribing in primary care for clinical syndromes subject to national recommendations to reduce antibiotic resistance, UK 1995–2011: analysis of a large database of primary care consultations. *J Antimicrob Chemother* 2014;69:3423–3430.
15. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. *N Engl J Med* 1989;321:1306–1311.
16. Oetgen ME, Blatz AM, Matthews A. Impact of clinical practice guideline on the treatment of pediatric femoral fractures in a pediatric hospital. *J Bone Joint Surg Am* 2015;97:1641–1646.
17. Kwon AJ, Roshal M, DeSancho MT. Clinical adherence to thrombophilia screening guidelines at a major tertiary care hospital. *J Thromb Haemost* 2016;14:982–986.
18. Meeker D, Knight TK, Friedberg MW, et al. Nudging guideline-concordant antibiotic prescribing: a randomized clinical trial. *JAMA Intern Med* 2014;174:425–431.
19. Meeker D, Linder JA, Fox CR, et al. Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices: a randomized clinical trial. *JAMA* 2016;315:562–570.
20. Gerber JS, Prasad PA, Fiks AG, et al. Effect of an outpatient antimicrobial stewardship intervention on broad-spectrum antibiotic prescribing by primary care pediatricians: a randomized trial. *JAMA* 2013;309:2345–2352.
21. Sun L, Klein EY, Laxminarayan R. Seasonality and temporal correlation between community antibiotic use and resistance in the United States. *Clin Infect Dis* 2012;55:687–694.
22. Elseviers MM, Ferech M, Vander Stichele RH, Goossens H, ESAC project group. Antibiotic use in ambulatory care in Europe (ESAC data 1997–2002): trends, regional differences and seasonal fluctuations. *Pharmacoepidemiol Drug Saf* 2007;16:115–123.
23. Achermann R, Suter K, Kronenberg A, et al. Antibiotic use in adult outpatients in Switzerland in relation to regions, seasonality and point of care tests. *Clin Microbiol Infect* 2011;17:855–661.
24. Patrick DM, Marra F, Hutchinson J, Monnet DL, Ng H, Bowie WR. Per capita antibiotic consumption: How does a North American jurisdiction compare with Europe? *Clin Infect Dis* 2004;39:11–17.
25. Dagan R, Barkai G, Givon-Lavi N, et al. Seasonality of antibiotic-resistant *Streptococcus pneumoniae* that causes acute otitis media: a clue for an antibiotic-restriction policy? *J Infect Dis* 2008;197:1094–1102.
26. Steinman MA, Gonzales R, Linder JA, Landefeld CS. Changing use of antibiotics in community-based outpatient practice, 1991–1999. *Ann Intern Med* 2003;138:525–533.
27. Steinman MA, Sauaia A, Maselli JH, Houck PM, Gonzales R. Office evaluation and treatment of elderly patients with acute bronchitis. *J Am Geriatr Soc* 2004;52:875–879.
28. Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. *JAMA* 2009;302:758–766.
29. Anderson DJ, Richet H, Chen LF, et al. Seasonal variation in *Klebsiella pneumoniae* bloodstream infection on 4 continents. *J Infect Dis* 2008;197:752–756.
30. Eber MR, Shardell M, Schweizer ML, Laxminarayan R, Perencevich EN. Seasonal and temperature-associated increases in gram-negative bacterial bloodstream infections among hospitalized patients. *PLoS One* 2011;6:e25298.
31. Falagas ME, Peppas G, Matthaiou DK, Karageorgopoulos DE, Karalis N, Theocharis G. Effect of meteorological variables on the incidence of lower urinary tract infections. *Eur J Clin Microbiol Infect Dis* 2009;28:709–712.
32. Cho Y, Badve SV, Hawley CM, et al. Seasonal variation in peritoneal dialysis-associated peritonitis: a multi-centre registry study. *Nephrol Dial Transplant* 2012;27:2028–2036.
33. Wang X, Towers S, Panchanathan S, Chowell G. A population based study of seasonality of skin and soft tissue infections: implications for the spread of CA-MRSA. *PLoS One* 2013;8:e60872.
34. Durkin MJ, Dicks KV, Baker AW, et al. Postoperative infection in spine surgery: does the month matter? *J Neurosurg Spine* 2015;23:128–134.
35. Durkin MJ, Dicks KV, Baker AW, et al. Seasonal variation of common surgical site infections: Does season matter? *Infect Control Hosp Epidemiol* 2015;36:1011–1016.
36. Gruskay J, Smith J, Kepler CK, et al. The seasonality of postoperative infection in spine surgery. *J Neurosurg Spine* 2013;18:57–62.
37. Gradel KO, Nielsen SL, Pedersen C, et al. Seasonal variation of *Escherichia coli*, *Staphylococcus aureus*, and *Streptococcus pneumoniae* bacteremia according to acquisition and patient characteristics: a population-based study. *Infect Control Hosp Epidemiol* 2016;1–8.
38. Lewis SS, Walker VJ, Lee MS, et al. Epidemiology of methicillin-resistant *Staphylococcus aureus* pneumonia in community hospitals. *Infect Control Hosp Epidemiol* 2014;35:1452–1457.
39. Beninca E, van Boven M, Hagenaars T, van der Hoek W. Space-time analysis of pneumonia hospitalisations in the Netherlands. *PLoS One* 2017;12:e0180797.
40. Dowell SF, Whitney CG, Wright C, Rose CE Jr, Schuchat A. Seasonal patterns of invasive pneumococcal disease. *Emerg Infect Dis* 2003;9:573–579.